发布求助
文献互助 智能选刊 最新文献

Oncoscience最新文献

筛选
英文 中文
Exploring oncogenic driver molecular alterations in Hispanic/Latin American cancer patients: A call for enhanced molecular understanding 探索西班牙裔/拉美裔癌症患者的致癌驱动分子改变：呼吁加强分子认识
Oncoscience Pub Date : 2024-04-22 DOI: 10.18632/oncoscience.597
Rafael Parra-Medina
{"title":"Exploring oncogenic driver molecular alterations in Hispanic/Latin American cancer patients: A call for enhanced molecular understanding","authors":"Rafael Parra-Medina","doi":"10.18632/oncoscience.597","DOIUrl":"https://doi.org/10.18632/oncoscience.597","url":null,"abstract":"","PeriodicalId":94164,"journal":{"name":"Oncoscience","volume":"11 24","pages":"34 - 35"},"PeriodicalIF":0.0,"publicationDate":"2024-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140674016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A very long and winding road: developing novel therapeutics for metastatic tumors. 漫长而曲折的道路：开发治疗转移性肿瘤的新型疗法。
Oncoscience Pub Date : 2024-02-09 eCollection Date: 2024-01-01 DOI: 10.18632/oncoscience.595
Paul Dent
{"title":"A very long and winding road: developing novel therapeutics for metastatic tumors.","authors":"Paul Dent","doi":"10.18632/oncoscience.595","DOIUrl":"https://doi.org/10.18632/oncoscience.595","url":null,"abstract":"","PeriodicalId":94164,"journal":{"name":"Oncoscience","volume":"11 ","pages":"32-33"},"PeriodicalIF":0.0,"publicationDate":"2024-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10856472/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139725518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
My battle with cancer. Part 1. 我与癌症的斗争第 1 部分.
Oncoscience Pub Date : 2024-01-03 eCollection Date: 2024-01-01 DOI: 10.18632/oncoscience.593
Mikhail V Blagosklonny
{"title":"My battle with cancer. Part 1.","authors":"Mikhail V Blagosklonny","doi":"10.18632/oncoscience.593","DOIUrl":"10.18632/oncoscience.593","url":null,"abstract":"<p><p>In January 2023, diagnosed with numerous metastases of lung cancer in my brain, I felt that I must accomplish a mission. If everything happens for a reason, my cancer, in particular, I must find out how metastatic cancer can be treated with curative intent. This is my mission now, and the reason I was ever born. In January 2023, I understood the meaning of life, of my life. I was born to write this article. In this article, I argue that monotherapy with targeted drugs, even when used in sequence, cannot cure metastatic cancer. However, preemptive combinations of targeted drugs may, in theory, cure incurable cancer. Also, I share insights on various topics, including rapamycin, an anti-aging drug that can delay but not prevent cancer, through my personal journey.</p>","PeriodicalId":94164,"journal":{"name":"Oncoscience","volume":"11 ","pages":"1-14"},"PeriodicalIF":0.0,"publicationDate":"2024-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10765422/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139379085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evolving insights in blood-based liquid biopsies for prostate cancer interrogation. 基于血液的液体活检在前列腺癌审讯中的发展见解。
Oncoscience Pub Date : 2023-11-30 eCollection Date: 2023-01-01 DOI: 10.18632/oncoscience.592
R Daniel Bonfil, Ghaith Al-Eyd
{"title":"Evolving insights in blood-based liquid biopsies for prostate cancer interrogation.","authors":"R Daniel Bonfil, Ghaith Al-Eyd","doi":"10.18632/oncoscience.592","DOIUrl":"10.18632/oncoscience.592","url":null,"abstract":"<p><p>During the last decade, blood sampling of cancer patients aimed at analyzing the presence of cells, membrane-bound vesicles, or molecules released by primary tumors or metastatic growths emerged as an alternative to traditional tissue biopsies. The advent of this minimally invasive approach, known as blood-based liquid biopsy, began to play a pivotal role in the management of diverse cancers, establishing itself as a vital component of precision medicine. Here, we discuss three blood-based liquid biopsies, namely circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) and tumor-derived exosomes, as they relate to prostate cancer (PCa) management. The advances achieved in the molecular characterization of these types of liquid biopsies and their potential to predict recurrence, improve responses to certain treatments, and evaluate prognosis, in PCa patients, are highlighted herein. While there is currently full clinical validation for only one CTC-based and one ctDNA-based liquid biopsy for patients with metastatic castration-resistant PCa, the adoption of additional methods is anticipated as they undergo standardization and achieve analytical and clinical validation. Advantages and disadvantages of different blood-based liquid biopsy approaches in the context of PCa are outlined herein, while also considering potential synergies through combinatory strategies.</p>","PeriodicalId":94164,"journal":{"name":"Oncoscience","volume":"10 ","pages":"69-80"},"PeriodicalIF":0.0,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138465251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Be mindful of potential pitfalls when using the Cre-LoxP system in cancer research 在癌症研究中使用Cre-LoxP系统时，要注意潜在的陷阱
Oncoscience Pub Date : 2023-11-14 DOI: 10.18632/oncoscience.591
{"title":"Be mindful of potential pitfalls when using the Cre-LoxP system in cancer research","authors":"","doi":"10.18632/oncoscience.591","DOIUrl":"https://doi.org/10.18632/oncoscience.591","url":null,"abstract":"","PeriodicalId":94164,"journal":{"name":"Oncoscience","volume":"38 27","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134953647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An immunoinformatics assessment of the cancer testis antigen, DDX53, as a potential early esophageal cancer antigen. 睾丸癌抗原DDX53作为潜在的早期食管癌抗原的免疫信息学评估。
Oncoscience Pub Date : 2023-11-10 eCollection Date: 2023-01-01 DOI: 10.18632/oncoscience.590
Peter Cheng, Konrad J Cios, Mallika Varkhedi, Vayda R Barker, Michelle Yeagley, Andrea Chobrutskiy, Boris I Chobrutskiy, George Blanck
{"title":"An immunoinformatics assessment of the cancer testis antigen, DDX53, as a potential early esophageal cancer antigen.","authors":"Peter Cheng, Konrad J Cios, Mallika Varkhedi, Vayda R Barker, Michelle Yeagley, Andrea Chobrutskiy, Boris I Chobrutskiy, George Blanck","doi":"10.18632/oncoscience.590","DOIUrl":"10.18632/oncoscience.590","url":null,"abstract":"<p><p>T-lymphocytes have been implicated in facilitating a pro-inflammatory, pro-tumorigenic microenvironment that worsens prognosis for esophageal carcinoma (ESCA). In this study, we identified tumor resident, T-cell receptor (TCR) complementarity determining region-3 (CDR3) amino acid sequences and employed an algorithm particularly suited to the big data setting to evaluate TCR CDR3-cancer testis antigen (CTA) chemical complementarities. Chemical complementarity of the ESCA TCR CDR3s and the cancer testis antigen DDX53 represented a disease-free survival (DFS) distinction, whereby the upper fiftieth percentile complementarity group correlated with worse DFS. The high TCR CDR3-DDX53 complementarity group also represented a greater proportion of tumor samples lacking DDX53 expression. These data and analyses raise the question of whether the TCR CDR3-DDX53 chemical complementarity assessment detected an ESCA immune response that selected for DDX53-negative cells?</p>","PeriodicalId":94164,"journal":{"name":"Oncoscience","volume":"10 ","pages":"59-66"},"PeriodicalIF":0.0,"publicationDate":"2023-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637345/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89721429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnosis and management of postoperative wound infections in the head and neck region. 头颈部术后伤口感染的诊断和处理。
Oncoscience Pub Date : 2023-10-04 eCollection Date: 2023-01-01 DOI: 10.18632/oncoscience.589
Filip Barbarewicz, Kai-Olaf Henkel, Florian Dudde
{"title":"Diagnosis and management of postoperative wound infections in the head and neck region.","authors":"Filip Barbarewicz,&nbsp;Kai-Olaf Henkel,&nbsp;Florian Dudde","doi":"10.18632/oncoscience.589","DOIUrl":"10.18632/oncoscience.589","url":null,"abstract":"","PeriodicalId":94164,"journal":{"name":"Oncoscience","volume":"10 ","pages":"56-58"},"PeriodicalIF":0.0,"publicationDate":"2023-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10549770/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41174703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The mutational signatures of cancer: can passengers set a direction for prognosis? 癌症的突变特征：乘客能为预后设定方向吗？
Oncoscience Pub Date : 2023-10-02 eCollection Date: 2023-01-01 DOI: 10.18632/oncoscience.588
Peeter Karihtala
{"title":"The mutational signatures of cancer: can passengers set a direction for prognosis?","authors":"Peeter Karihtala","doi":"10.18632/oncoscience.588","DOIUrl":"https://doi.org/10.18632/oncoscience.588","url":null,"abstract":"","PeriodicalId":94164,"journal":{"name":"Oncoscience","volume":"10 ","pages":"54-55"},"PeriodicalIF":0.0,"publicationDate":"2023-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10545096/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41125376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Activity of pazopanib in EWSR1-NFATC2 translocation-associated bone sarcoma. 帕唑帕尼在EWSR1-NFATC2易位相关骨肉瘤中的活性。
Oncoscience Pub Date : 2023-09-20 eCollection Date: 2023-01-01 DOI: 10.18632/oncoscience.587
Mohamed A Gouda, Maria A Zarzour, Ara A Vaporciyan, Kalevi Kairemo, Hubert H Chuang, Vivek Subbiah
{"title":"Activity of pazopanib in <i>EWSR1-NFATC2</i> translocation-associated bone sarcoma.","authors":"Mohamed A Gouda,&nbsp;Maria A Zarzour,&nbsp;Ara A Vaporciyan,&nbsp;Kalevi Kairemo,&nbsp;Hubert H Chuang,&nbsp;Vivek Subbiah","doi":"10.18632/oncoscience.587","DOIUrl":"https://doi.org/10.18632/oncoscience.587","url":null,"abstract":"<p><p>Pazopanib is a multi-kinase inhibitor that is currently approved for treatment of advanced renal cell carcinoma and chemotherapy-refractory soft tissue sarcoma. In this case report, we discuss the case of a patient with a <i>EWSR1-NFATC2</i> fusion positive bone sarcoma who had exceptional tumor control through using pazopanib and surgery for an overall duration exceeding 5 years. We also review the literature on <i>EWSR1-NFATC2</i> translocation-associated sarcomas and use of pazopanib in bone sarcomas.</p>","PeriodicalId":94164,"journal":{"name":"Oncoscience","volume":"10 ","pages":"44-53"},"PeriodicalIF":0.0,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511123/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41143758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multi-disciplinary management of recurrent gastrointestinal stromal tumor harboring KIT exon 11 mutation with the switch-control kinase inhibitor ripretinib and surgery. 应用开关控制激酶抑制剂瑞普替尼对携带KIT外显子11突变的复发性胃肠道间质瘤进行多学科治疗和手术。
Oncoscience Pub Date : 2023-09-20 eCollection Date: 2023-01-01 DOI: 10.18632/oncoscience.586
Mohamed A Gouda, Filip Janku, Neeta Somaiah, Kelly K Hunt, Sireesha Yedururi, Vivek Subbiah
{"title":"Multi-disciplinary management of recurrent gastrointestinal stromal tumor harboring KIT exon 11 mutation with the switch-control kinase inhibitor ripretinib and surgery.","authors":"Mohamed A Gouda,&nbsp;Filip Janku,&nbsp;Neeta Somaiah,&nbsp;Kelly K Hunt,&nbsp;Sireesha Yedururi,&nbsp;Vivek Subbiah","doi":"10.18632/oncoscience.586","DOIUrl":"https://doi.org/10.18632/oncoscience.586","url":null,"abstract":"<p><p>Ripretinib is a tyrosine kinase inhibitor that was approved by the United States FDA in 2020 for treatment of advanced gastrointestinal stromal tumor (GIST) in patients who received prior treatment with three or more tyrosine kinase inhibitors. In this case report, we show the durable clinical benefit achieved in a patient with GIST by using ripretinib and repeated timely surgical resection of limited disease progression. The total time on ripretinib was 43 months which is longer than the current reported data from ripretinib clinical trials. Such approach for using multi-disciplinary disease management can improve the durability of response to tyrosine kinase inhibitors, including ripretinib, and associated clinical outcomes.</p>","PeriodicalId":94164,"journal":{"name":"Oncoscience","volume":"10 ","pages":"38-43"},"PeriodicalIF":0.0,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511119/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41158950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信